Conflicts of interest. Very balanced Lilly and team, AZ and BMS
|
|
- Lydia Martin
- 5 years ago
- Views:
Transcription
1 Conflicts of interest Very balanced Lilly and team, AZ and BMS
2 Distal microcirculation receives platelet microparticles Release TxA 2 and plugs microcapillaries
3 Healthy vascular endothelium Prevents (antithrombotic factors) CD39 (ectoadpase), prostaglandin, nitric oxide, heparin, matrix metalloproteinase-9, protein S, and thrombomodulin
4 Risk factors.just add wall stress Collagen type 1 Very thin cap Large atheroma volume Increased necrotic core Thin cap Plaque burden >70% Risk factors in ACS for a CV event Minimal luminal area <4 mm 2 Collagen type III Very thick cap (reparative) 22% event rate / yr PROSPECT trial Motoyama Moreno et al JACC img 2012;5:178
5 Ruptured plaque with prothrombosis and platelet microparticles chest pain
6 Acute coronary syndrome Unstable angina Negative biomarkers NSTEMI Positive biomarkers ST elevation MI Positive biomarkers Higher biomarkers---higher mortality
7 Elevated Cardiac TnI Predicts Increased Mortality at 42 Days in Patients With ACS Patients with unstable angina or non Q wave MI enrolled in a multicenter study (N=1,404) Cardiac TnI (ng/ml) n Mortality at 42 days (%) 0 to < to < to < to < to < Risk Ratio (95% CI) Antman EM, et al. N Engl J Med. 1996;335(18):
8 Increased 1-year Survival in TnI- Negative ACS Patients Subgroup of patients (n=734) with suspected ACS enrolled in a phase III study -TnI +TnI Newby LK, et al. Circulation. 1998;98(18):
9 Events leading to Reperfusion Induced inflammatory Injury Time is Muscle % Necrosis Most viable area subepicardial tissue minutes 3 hours 6 hours Closed molecular changes during MI.pdf Time of reperfusion Ambrosio Am Heart J 1999;138:s69 Reimer KA. Lab Invest Jun;40(6):633-44
10 LV remodeling correlates with death Unstable angina Non STEMI Acute Cellular protection Acute MI (ST; + biomarkers) Long-term Matrix remodeling BB and ACEI
11 Age- and Sex-Adjusted Incidence Rates of Acute Myocardial Infarction, 1999 to 2008 N Engl J Med 2010;362:
12 ACS, patients with diabetes and UA/NSTEMI the risk of similar to non diabetes patient with STEMI (7.2% vs 8.1%) UA/NSTEMI STEMI TIMI study group ( 11 trials) patients Cumulative Incidence of All- Cause Mortality through 1 year after ACS Diabetes No diabetes Diabetes No diabetes Thrombolysis in Myocardial Infarction (TIMI) Study Group JAMA. 2007;298(7):
13 Basic science-cardiovascular hematology
14 oxldl & monocyte derived tissue factors activate thrombosis and inflammation Injury to endothelial wall LDL infiltrate wall Autoantibodies against oxldl oxldl Monocytes recruited and up LDL via TLR4 receptor Activation of platelets / tissue factor Microparticle (MP)TF activity
15 Humans with FH have increased prothrombotic / inflammatory risk TAT- thrombin-anti-thrombin complex JCI 2012;122:558
16 Statin significantly lower tissue factor activity TAK-242-inhibits TLR-4 JCI 2012;122:558
17 Statins work N engl j med 366;19 nejm.org may 10, 2012:1752
18 Lipids are involved in the prothrombotic state
19 Statins significantly reduce inflammation and prothrombosis Reduce LDL in lipid core Reduce oxidative stress Reduce oxidation of LDL Inhibit expression of CD36/TLR4/TLR6 Inhibit expression of monocyte tissue factor Inhibit release of tissue factor + microparticles
20 Platelets are activated by many conditionsincreasing prothrombotic state Anti-thrombins Agonist Receptor LDL Activation of platelets is mediated by CD36 CD-36 Platelet IP3 Arachidonic acid Prost G2 Prostacyclin ADP TxA 2 others Thromboxane A2 IP3 ADP ADP receptor Irreversible Oral clopidogrel/ prasugrel Inflamed MONOCYTE Ticagrelor (reversible) 2b3a receptor oxldl JCI 2012;122:558 Nat Med. 2007;13(9): Fibrinogen 2b3a receptor
21 Thrombin / necrotic core are the most potent activator of platelets High Glucose Activation of PKC & NFkB Induce PAR-4 expression VSMC Thrombin Responsiveness Enhancing vascular response to thrombin Control Dangwal et Arterioscler Thromb Vasc Biol. Mar 2011;31:xxx High Glucose
22 Thrombin is the most potent activator of platelets PAR-4 Increases Phosphoinositide hydrolysis Thromboxane A2 formation Increases Ca++ Suppresses camp by blocking adenylyl cyclase PAR 1 and 4 in humans PAR 1 most receptors on platelets PAR 4 increased with high glucose Non-Diabetes PAR 1 found on Platelets VSMCs Endothelial cells Fibroblasts Neurones PAR 4 located on Platelets VSMCs Others Diabetes Purple (b and e), PAR-4 on human saphenous vein Dangwal et Arterioscler Thromb Vasc Biol. Mar 2011;31:xxx
23 Platelet receptors Thrombin / necrotic core are the most potent agonist for human platelets, whereas serotonin and epinephrine are weak agonists Size of arrow = strength of stimulus Blood, Vol 93, No 10 (May 15), 1999: pp
24 Tissue factor Collagen Factor VIIa X IX IXa Warfarin (Vit K antagonist) Synthesis of factors II, VII, IX, and X requires vitamin K Propagation Key position VIIa Va Xa Direct thrombin inhibitors Platelets II (prothrombin) Thrombin Activation Thrombin (IIa) Fibrinogen Fibrin Aggregation Clotting
25 Inflammation leads to increased prothrombosis Vascular inflammation Prothrombosis Positive staining (brown) for C-reactive protein (CRP) in macrophage foam cells (arrows) in intima Platelets to damaged areas of blood vessels and contribute to the formation of clots. Turk et al J Appl Physiol 2003;95: NIH.gov
26 GOLD trial-how much platelet inhibition do you need Summary of anti-platelet trials TIMI-38 Prasugrel, age less than 75 and pre cath PLATO- Ticagrelor, >75 and all comers Rivaroxaban in Patients with a Recent Acute Coronary Syndrome ACS clinical trials
27 GOLD Trial: PCI major adverse cardiac events with poor platelet inhibition N=500 PCI patients b3a inhibitors MACE Composite of death, myocardial infarction, and urgent target vessel revascularization P<0.006 P< <95% INHIB 10 min >95% INHIB 10 min <70% 8 hrs >70% 8 hrs Circulation. 2001;103:
28 Landmark anti-platelet trials in ACS Placebo arm Ticagrelor NEJM 2009;361:1108
29 TIMI 38: Study Design ACS (STEMI or UA/NSTEMI) & Planned PCI ASA required Clopidogrel 300 mg LD 75 mg MD Double-blind N = 13,608 Prasugrel 60 mg LD 10 mg MD 1 o endpoint: CV death, MI, Stroke 2 o endpoints: Stent Thrombosis CV death, MI, Stroke, Rehosp-Rec Isch 30, 90 day: CV death, MI, Stroke, 30, 90 day: CV death, MI, UTVR Safety endpoints: TIMI major bleeds, Life-threatening bleeds Key Substudies: Pharmacokinetic, Genomic Median duration of therapy:12 months Wiviott SD, et al. N Engl J Med. 2007;357:
30 Primary Endpoint (CV death, MI, stroke, %) 15 TRITON TIMI 38 (ACS) HR 0.77 P = Clopidogrel 12.1 (781) 10 5 HR 0.80 P = Prasugrel 9.9 (643) HR 0.81 ( ) P = NNT = 46 0 ITT = 13,608 LTFU = 14 (0.1%) Days Wiviott SD, et al. N Engl J Med. 2007;357:
31 TIMI 38 Bleeding Endpoints Overall cohort at 15 months Wiviott SD, et al. N Engl J Med. 2007;357:
32 Ticagrelor vs Clopidogrel for ACS: PLATO PLATelet inhibition and patient Outcomes In NSTEMI and STEMI, current guidelines recommend 12 months aspirin and clopidogrel Efficacy of clopidogrel is hampered by Slow and variable transformation to the active metabolite Modest and variable platelet inhibition Increased risk of bleeding Risk of stent thrombosis and MI in poor responders Wallentin L, et al. N Engl J Med. 2009;361(11):
33 PLATO Study Design NSTEMI-ACS (moderate-to-high risk) STEMI (if primary PCI) Clopidogrel-treated or -naive; randomized within 24 hours of index event (N = 18,624) Clopidogrel If pre-treated, no additional loading dose; if naive, standard 300 mg loading dose, then 75 mg qd maintenance; (additional 300 mg allowed pre-pci) Ticagrelor 180 mg loading dose, then 90 mg bid maintenance; (additional 90 mg pre-pci) 6 12-month exposure Primary endpoint: Vascular death + MI + Stroke Primary safety endpoint: Total major bleeding Wallentin L, et al. N Engl J Med. 2009;361(11):
34 Cumulative Incidence (%) Primary Efficacy Endpoint Clopidogrel Ticagrelor HR 0.84 (95% CI ) P = No. at risk Days after Randomization Ticagrelor 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Clopidogrel 9,291 8,521 8,362 8,124 6,743 5,096 4,047 Positive efficacy effect not observed in North American subgroup Wallentin L, et al. N Engl J Med. 2009;361(11):
35 Cumulative Incidence (%) Cumulative Incidence (%) Secondary Efficacy Endpoints Myocardial Infarction Cardiovascular Death 7 Clopidogrel Ticagrelor Clopidogrel Ticagrelor 2 1 HR 0.84 (95% CI ), P = HR 0.79 (95% CI ), P = Days after Randomization Days after Randomization Wallentin L, et al. N Engl J Med. 2009;361(11):
36 PLATO -major endpoints Ticagrelor (n=9,333) Clopidogrel (n=9,291) HR for (95% CI) p value 864 (9.8) 1,014 (11.7) 0.84 ( ) < (10.2) 1,065 (12.3) 0.84 ( ) < ,290 (14.6) 1,456 (16.7) 0.88 ( ) < (5.8) 593 (6.9) 0.84 ( ) (4.0) 442 (5.1) 0.79 ( ) (1.5) 106 (1.3) 1.17 ( ) (4.5) 506 (5.9) 0.78 ( ) <0.001 The percentages are K-M estimates of the rate of the endpoint at 12 months. N Engl J Med 2009; 361:
37
38 K-M Estimated Rate (% per year) Time to Major Bleeding Primary Safety Event Ticagrelor Clopidogrel HR 1.04 (95% CI ), P = Days from First IP Dose Increased frequency of dyspnea observed with ticagrelor (13.8% vs 7.8%, P < 0.001) Wallentin L, et al. N Engl J Med. 2009;361(11):
39 NDA Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting es/.../ucm pdf P. 106
40 CV Death, MI, or stroke (K-M%) at 12 months PLATO: use low dose aspirin n=956 n=15,439 n=1,052 BRILINTA Clopidogrel + aspirin + aspirin Aspirin 100 mg HR 0.77 (95% CI: ) BRILINTA Clopidogrel + aspirin + aspirin Aspirin >100 mg - <300 mg HR 0.99 (95% CI: ) BRILINTA Clopidogrel + aspirin + aspirin Aspirin 300 mg HR 1.45 (95% CI: ) Caution
41 ASA dosage and Ticagrelor-CR advisory committee Platelet testing of active compounds and metabolites of ticagrelor, prasugrel and clopidogrel Panel of receptors and enzymes Found NO potential off target interactions Thromboxane A2 are potently inhibited by all 3 Hypothesis only High degree of p2y12 inhibition with all 3 agents Addition of ASA would not further improve platelet inhibition.but higher doses could reduce prostacyclin (PGI2) longer thus unopposed reduction of PGI2 leaves Thrombogenic and vasoconstrictive effect of ASA Short term reduces prostacyclin ASA-usually Blocks COX 1- reducing TxA2 Prostacyclin (PGI 2 ) chiefly prevents formation of the platelet plug and powerful vasodilator P86 NDA
42 NDA conclusion relative to ASA and Ticagrelor High-level P2Y 12 antagonism can inhibit both ADP-dependent and platelet TXA 2 -dependent pathways of platelet activation independently of ASA ASA dose-dependently inhibits TXA 2 synthesis, which reaches maximum effect at relatively low doses ASA reduces PGI 2 levels dose-dependently which could, particularly at high doses, negatively affect endothelial function, potentially facilitate platelet activation, and ultimately contribute to increased thrombotic risk.
43 P127 NDA
44 AHA/ACCF Secondary Prevention and Risk Reduction Therapy Guidelines: Use of Antiplatelets Class I Recommendation A P2Y 12 receptor antagonist in combination with aspirin is indicated in patients after ACS (Level of Evidence: A) For patients receiving a bare-metal stent or drug-eluting stent during PCI for ACS, clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily should be given for at least 12 months (Level of Evidence: A) Class IIa Recommendation After PCI, it is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses (Level of Evidence: B)
45 ACCF/AHA/SCAI Guidelines for PCI Class I Recommendations A loading dose of a P2Y 12 receptor inhibitor should be given to patients undergoing PCI with stenting (Level of Evidence: A). Options include (Level of Evidence: B): Clopidogrel 600 mg (ACS and non-acs patients) Prasugrel 60 mg (ACS patients) Ticagrelor 180 mg (ACS patients) The duration of P2Y 12 inhibitor therapy after stent implantation should generally be as follows: In patients receiving a stent (bare-metal stent [BMS] or drug-eluting stent [DES]) during PCI for ACS, P2Y 12 inhibitor therapy should be given for at least 12 months. Options include clopidogrel 75 mg daily, prasugrel 10 mg daily, and ticagrelor 90 mg twice daily (Level of Evidence: B) Class IIa After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses (Level of Evidence: B)
46 4 take home points Time is muscle: open artery by PCI wins over drugs if done <90 minutes Platelets are extremely important in the prothrombotic state with inflammation and LDL Newer anti-platelet drugs block better than clopidogrel..but more bleeding Besure to use low dose ASA with ticagrelor Thank you
47
Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationΚωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationINNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.
INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies. José G. Díez, MD, FACC, FSCAI Associate Professor of Medicine, Baylor College of Medicine Hall Garcia
More informationUpdate on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationDisclosures. Research consulting with: Sanofi-Regeneron Pfizer The Medicines Company Astra Zeneca
Antiplatelet Therapy in Coronary Artery Disease -2015 What are the roles for newer therapies? How do you decide what to cover? R. Scott Wright, MD, FACC, FESC, FAHA Professor of Medicine, Mayo Clinic College
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationClopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent
Clopidogrel When For What For How Long T Benjanuwattra Chiang Mai Heart Cent Evidence Based Medicine I don t want to put you to sleep But want you to be fully alert Atherothrombosis: A Generalized and
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationAntiplatelet Therapy. Briain Mac Neill
Antiplatelet Therapy Briain Mac Neill Galway University Hospital & National University of Ireland Galway Milestones in ACS Management Anti-Thrombin Rx Heparin LMWH Bivalirudin Anti-Platelet Rx Aspirin
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationDOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands
DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands RECENT DEVELOPMENTS Better anti-platelet agents: Prasugrel and Ticagrelor to replace
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationImproving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome
Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome E. Magnus Ohman, MB, FRCPI, FESC, FACC Professor of Cardiovascular Medicine The Kent and Siri Rawson
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
More informationCoronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy
Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More information